TY - JOUR
T1 - Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices
AU - Del Mazo-Barbara, Anna
AU - Mirabel, Clémentine
AU - Nieto, Valentín
AU - Reyes, Blanca
AU - García-López, Joan
AU - Oliver-Vila, Irene
AU - Vives, Joaquim
PY - 2016/9/1
Y1 - 2016/9/1
N2 - © 2016 Future Medicine Ltd. Aim: Computerized systems (CS) are essential in the development and manufacture of cell-based medicines and must comply with good manufacturing practice, thus pushing academic developers to implement methods that are typically found within pharmaceutical industry environments. Materials & methods: Qualitative and quantitative risk analyses were performed by Ishikawa and Failure Mode and Effects Analysis, respectively. Results: A process for qualification of a CS that keeps track of environmental conditions was designed and executed. The simplicity of the Ishikawa analysis permitted to identify critical parameters that were subsequently quantified by Failure Mode Effects Analysis, resulting in a list of test included in the qualification protocols. Conclusion: The approach presented here contributes to simplify and streamline the qualification of CS in compliance with pharmaceutical quality standards.
AB - © 2016 Future Medicine Ltd. Aim: Computerized systems (CS) are essential in the development and manufacture of cell-based medicines and must comply with good manufacturing practice, thus pushing academic developers to implement methods that are typically found within pharmaceutical industry environments. Materials & methods: Qualitative and quantitative risk analyses were performed by Ishikawa and Failure Mode and Effects Analysis, respectively. Results: A process for qualification of a CS that keeps track of environmental conditions was designed and executed. The simplicity of the Ishikawa analysis permitted to identify critical parameters that were subsequently quantified by Failure Mode Effects Analysis, resulting in a list of test included in the qualification protocols. Conclusion: The approach presented here contributes to simplify and streamline the qualification of CS in compliance with pharmaceutical quality standards.
KW - academic institution
KW - cell therapy
KW - computerized system
KW - Failure Mode Effects Analysis
KW - good manufacturing practice
KW - Ishikawa
KW - qualification
KW - validation
U2 - 10.2217/rme-2016-0066
DO - 10.2217/rme-2016-0066
M3 - Article
SN - 1746-0751
VL - 11
SP - 521
EP - 528
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 6
ER -